TipRanks
Advertisement
Advertisement
Crystalys Therapeutics – Weekly Recap
PremiumPrivate CompaniesCrystalys Therapeutics – Weekly Recap
1M ago
Crystalys Therapeutics Leadership Targets Visibility at Global Healthcare Conference
Premium
Private Companies
Crystalys Therapeutics Leadership Targets Visibility at Global Healthcare Conference
1M ago
Crystalys Therapeutics Highlights Gout Program Targeting Underserved Patient Population
Premium
Private Companies
Crystalys Therapeutics Highlights Gout Program Targeting Underserved Patient Population
1M ago
Crystalys Therapeutics Highlights Gout Program Strategy and Dotinurad Focus
PremiumPrivate CompaniesCrystalys Therapeutics Highlights Gout Program Strategy and Dotinurad Focus
2M ago
Crystalys Therapeutics Draws Media Attention as $130 Million Series B Powers Late-Stage Gout Program
Premium
Private Companies
Crystalys Therapeutics Draws Media Attention as $130 Million Series B Powers Late-Stage Gout Program
2M ago
Crystalys Therapeutics Highlights $130 Million Series B and Gout Program in Media Coverage
Premium
Private Companies
Crystalys Therapeutics Highlights $130 Million Series B and Gout Program in Media Coverage
2M ago
Crystalys Therapeutics Highlights Investor Engagement and Gout Program Focus
PremiumPrivate CompaniesCrystalys Therapeutics Highlights Investor Engagement and Gout Program Focus
3M ago
Crystalys Therapeutics Advances Dotinurad Through Multiple Late-Stage Gout Trials
Premium
Private Companies
Crystalys Therapeutics Advances Dotinurad Through Multiple Late-Stage Gout Trials
3M ago
Crystalys Therapeutics Highlights Dotinurad Program at BIO 2026
Premium
Private Companies
Crystalys Therapeutics Highlights Dotinurad Program at BIO 2026
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―